M&A / Deals Parabilis follows hefty Regeneron deal with IPO push BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritisNext: Beam one-ups Wave as both show promise of genetic editing for AATD Related Stories M&A / Deals Gilead inks $140M API supply deal, tightening ties to Korean manufacturer pharminent May 22, 2026 M&A / Deals GBL joins CVC in 10.7bn takeover bid for Recordati pharminent May 22, 2026 M&A / Deals Gilead Sciences completes Tubulis acquisition for $5bn pharminent May 22, 2026
